Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Immunome (IMNM) over the last 3 years, with Sep 2025 value amounting to $45.4 million.

  • Immunome's Cash from Financing Activities rose 14781.64% to $45.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.6 million, marking a year-over-year decrease of 17.50%. This contributed to the annual value of $240.5 million for FY2024, which is 106.63% up from last year.
  • Per Immunome's latest filing, its Cash from Financing Activities stood at $45.4 million for Q3 2025, which was up 82,625.45% from -$55,000 recorded in Q2 2025.
  • In the past 5 years, Immunome's Cash from Financing Activities registered a high of $219.4 million during Q1 2024, and its lowest value of -$55,000 during Q2 2025.
  • Moreover, its 3-year median value for Cash from Financing Activities was $32.7 million (2024), whereas its average is $56.4 million.
  • In the last 5 years, Immunome's Cash from Financing Activities skyrocketed by 645,326.47% in 2024 and then plummeted by 107.93% in 2025.
  • Over the past 3 years, Immunome's Cash from Financing Activities (Quarterly) stood at $55.5 million in 2023, then slumped by 63.81% to $20.1 million in 2024, then skyrocketed by 14,781.64% to $45.4 million in 2025.
  • Its last three reported values are $45.4 million in Q3 2025, -$55,000 for Q2 2025, and $162.2 million during Q1 2025.